Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $47.00 at HC Wainwright

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective upped by HC Wainwright from $45.00 to $47.00 in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock.

SNDX has been the topic of several other research reports. Citigroup increased their target price on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 16th. Stifel Nicolaus boosted their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. JPMorgan Chase & Co. decreased their price target on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Bank of America increased their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. Finally, UBS Group initiated coverage on shares of Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $36.10.

Syndax Pharmaceuticals Trading Up 8.4 %

SNDX opened at $21.35 on Wednesday. The stock has a market capitalization of $1.82 billion, a P/E ratio of -6.32 and a beta of 0.92. The stock has a 50-day moving average price of $19.06 and a 200-day moving average price of $20.32. Syndax Pharmaceuticals has a 12-month low of $13.14 and a 12-month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same period in the prior year, the company earned ($0.73) EPS. On average, equities research analysts predict that Syndax Pharmaceuticals will post -3.66 EPS for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Simplify Asset Management Inc. lifted its holdings in Syndax Pharmaceuticals by 62.5% in the third quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock worth $2,352,000 after buying an additional 46,992 shares during the period. Atria Investments Inc bought a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth approximately $364,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Syndax Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,367 shares of the company’s stock valued at $315,000 after purchasing an additional 6,383 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at approximately $30,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).